EUCTR2010-020057-13-DE进行中（未招募）不适用
Proof-of-concept-study to Evaluate the Efficacy and Tolerability of Repeated Versus Single Treatment with Botulinum-Toxin (Vistabel®) Treatment in Combination with a Hyaluronic Acid (Juvederm-Ultra® 2) in Patients with Glabellar Frown Lines
Dermatologikum Hamburg0 个研究点开始时间: 2010年4月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Moderate to severe glabellar frown lines at rest (grade 2 to 3 on the FWS) as assessed by the investigator according to the FWS
- •Female and male subjects between 18 to 65 years in good general health
- •A subject of childbearing potential agrees to use one of the following contraceptive methods for the duration of the study:
- •oStrict abstinence (exception: male partner with a vasectomy for at least 3 months prior to study entry is allowed)
- •oCombined oral, implanted or injectable contraceptives on a stable dose for at least 3 months prior to study entrance
- •oIntrauterine device (IUD) inserted for at least 1 month prior to study entrance
- •Willingness to adhere to the study visit schedule, concomitant therapy prohibitions, treatment regimen and study procedures described in the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior treatment with Botulinum toxin within the last 6 months in the glabellar area
- •Prior treatment with non permanent filler in the glabellar area within the last 12 months
- •Any prior surgery affecting the glabellar area
- •Permanent filler or any other permanent implants in the glabellar area
- •Any planned cosmetic procedure (e.g. facelift, resurfacing (laser, photomodulation, IPL, radio frequency, dermabrasion, chemical peel or other ablative or non-ablative procedures) in the glabellar area during the course of the study
- •Marked facial asymmetry or ptosis of eyelid and/or eyebrow
- •A medical condition that may put the subject at increased risk with exposure to Botulinum toxin type A (Vistabel®) including but not limited to myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic lateral sclerosis or any other neuromuscular dysfunction
- •Any disease or medical condition that in the investigators opinion may put the subject at general risk and therefore would prevent participation in the clinical trial (including but not limited to cardiovasclar diseases, arrhythmia etc.)
- •Subjects with an active inflammation, or active infection, cancerous or pre-cancerous lesion, or unhealed wound in the glabellar area
- •Subjects with a history of an autoimmune disease or under immunosuppressive therapy or therapy used to decrease the body’s immune response
- •History of facial nerve palsy
- •History of narrow-angle glaucoma
- •History of dysphagia, respiratory or speech disorders
- •History of bleeding disorders
- •Administration of anti-platelet or other medication with anticoagulant effect (e.g. acetylsalicylic acid, phenprocoumon, heparin injections, clopidogrel or others)
- •Administration of agents such as aminoglycoside antibiotics that might interfere with the neuromuscular function
- •Intake of drugs that might induce the productions of antibodies against acethycholine receptors (e.g. D-Penicillamin)
- •Intake of drugs that might antagonize the onset of paralysis activity of botulinum toxins (such as the aminoquinolines chloroquine and hydroxyl-chloroquine)
- •Subjects with a history of anaphylaxis or multiple severe allergies
- •Subjects with a history of allergies or other side effects to lidocaine (or any amide-based anesthetic), hyaluronic acid products, Gram-positive bacterial protein, or other components of the study compound
- •Subjects with a history of excessive scarring (e.g., hypertrophic scarring and keloid formulations) and pigmentation disorders
- •Pregnancy, nursing or planning of pregnancy during the trial period or no usage of appropriate methods of contraception by females of childbearing potential
- •Subjects who are – in the opinion of the investigator – unreliable, and/or non-compliant, and/or who present with any condition or treatment that may interfere with the conduct of the trial (e.g. psychiatric problems, evidence of drug or alcohol abuse)
- •Participation in any other clinical trial within 30 days prior or during this trial
研究者
相似试验
已完成
1 期
An Intralesional Injection Study of DUR-928 in Psoriasis PatientsPsoriasisSkin - Dermatological conditionsACTRN12616001077459INC Research12
进行中（未招募）
不适用
Proof-of-concept study: Prüfung der Wirksamkeit und der Verträglichkeit von Botulinum-Toxin (Xeomin®) bei der Behandlung von Krähenfüßen im Vergleich zu Dysport® im intraindividuellen VergleichModerate to severe crow`s feetMedDRA version: 9.1Level: LLTClassification code 10052611Term: Crow's feetEUCTR2008-001157-18-DEDermatologikum Hamburg
进行中（未招募）
不适用
Proof-of-concept study: Prüfung der Wirksamkeit und der Verträglichkeit von Botulinum-Toxin (Xeomin®) bei der Behandlung von Krähenfüßen im Vergleich zu Vistabel® im intraindividuellen VergleichEUCTR2008-001158-42-DEDermatologikum Hamburg
进行中（未招募）
1 期
A Proof of concept study to investigate the effect of the antiviral medication Telbivudine in patients with inflammatory heart muscle disease caused by the ParvovirusParvovirus B19-induced inflammatory cardiomyopathyEUCTR2016-004825-17-DECharité Universitätsmedizin Berlin25
进行中（未招募）
不适用
Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHPulmonary arterial hypertensionEUCTR2007-003975-38-NLErgonex Pharma GmbH84